Ascendiant Capital Maintains Buy on Envoy Medical, Raises Price Target to $8.75
Portfolio Pulse from Benzinga Newsdesk
Ascendiant Capital has maintained a Buy rating on Envoy Medical and raised the price target from $8.5 to $8.75.
September 03, 2024 | 9:38 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ascendiant Capital has reaffirmed its Buy rating on Envoy Medical and increased the price target from $8.5 to $8.75, indicating a positive outlook.
The increase in the price target from $8.5 to $8.75 by Ascendiant Capital suggests a positive outlook for Envoy Medical. Maintaining the Buy rating indicates confidence in the company's future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100